TransMedics (TMDX) Receivables (2018 - 2026)

TransMedics has reported Receivables for 9 years, with the latest figure at $90.7 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 36.12% year-over-year to $90.7 million; the trailing twelve-month figure through Mar 2026 stood at $90.7 million (down 36.12% YoY), and the FY2025 full-year result was $84.3 million, down 13.75% from the prior year.
• Receivables for Q1 2026 stood at $90.7 million, up from $84.3 million in the prior quarter.
• The five-year high for Receivables was $142.0 million in Q1 2025, with the low at $11.7 million in Q1 2022.
• Average Receivables over 5 years is $67.1 million, with a median of $80.7 million recorded in 2025.
• Year-over-year, Receivables surged 430.96% in 2022 and slumped 36.12% in 2026.
• Tracing TMDX's Receivables over 5 years: stood at $27.6 million in 2022, then surged by 130.26% to $63.6 million in 2023, then jumped by 53.71% to $97.7 million in 2024, then declined by 13.75% to $84.3 million in 2025, then climbed by 7.65% to $90.7 million in 2026.
• The last three Receivables figures came in at $90.7 million (Q1 2026), $84.3 million (Q4 2025), and $80.7 million (Q3 2025), per Business Quant data.

Peer Comparison